Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The phase 3 TRAILRUNNER-ALZ 1 study, officially titled “Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer’s Disease,” evaluates Eli Lilly’s remternetug in people with early Alzheimer’s disease. It aims to show if lowering amyloid plaques can safely slow disease at a stage where treatment may preserve function.
The study tests remternetug, also known as LY3372993, an antibody drug designed to remove amyloid from the brain. It is given either by intravenous (IV) infusion or by subcutaneous (SC) injection, with placebo used as a comparator during the main treatment period.
This is an interventional, randomized trial where participants are assigned to different treatment arms. It uses a parallel-group model, with both patients and investigators blinded during the main phase, and the main goal is to treat Alzheimer’s disease rather than just observe it.
The trial started after its initial submission on 14 July 2022, marking the formal launch of enrollment and dosing. The last update was filed on 20 May 2026, after the study reached “completed” status, signaling that treatment and follow-up are done and the focus now shifts toward data analysis and potential disclosure.
Primary completion, when core outcome data are collected, is key for investors because it often precedes topline result releases that can move Eli Lilly’s stock. The full completion date frames when regulators and payers might see a full data package, affecting expectations for the Alzheimer’s portfolio and timelines versus rivals like Biogen/Eisai and Roche.
The latest update confirms that the pivotal work on remternetug is now finished, which should sharpen market focus on the probability of success, label scope, and pricing power in an emerging disease-modifying Alzheimer’s market. Any strong safety and amyloid-clearing signals would reinforce Lilly’s positioning in neurology and could support a higher valuation multiple than peers with less advanced programs.
For now, the study is completed and recently updated, with further details available on the ClinicalTrials.gov portal.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.